NYSE:NVS - Novartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$76.41 -0.89 (-1.15 %)
(As of 04/19/2019 01:05 AM ET)
Previous Close$77.30
Today's Range$75.96 - $77.35
52-Week Range$72.30 - $96.31
Volume4.46 million shs
Average Volume2.30 million shs
Market Capitalization$176.51 billion
P/E Ratio15.01
Dividend Yield2.38%
Beta0.68
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; and TRIO. The company was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone011-41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.90 billion
Cash Flow$7.6871 per share
Book Value$34.07 per share

Profitability

Net Income$12.61 billion

Miscellaneous

Employees125,161
Outstanding Shares2,310,000,000
Market Cap$176.51 billion
Next Earnings Date4/24/2019 (Confirmed)
OptionableOptionable

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, January 31st. Shareholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is an increase from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings results on Wednesday, January, 30th. The company reported $1.24 EPS for the quarter, missing analysts' consensus estimates of $1.33 by $0.09. The business earned $13.27 billion during the quarter, compared to the consensus estimate of $13.33 billion. Novartis had a net margin of 24.30% and a return on equity of 15.66%. The firm's revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.21 EPS. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Novartis.

How can I listen to Novartis' earnings call?

Novartis will be holding an earnings conference call on Wednesday, April 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for NVS?

16 brokerages have issued twelve-month target prices for Novartis' stock. Their predictions range from $74.71 to $105.00. On average, they anticipate Novartis' stock price to reach $87.5650 in the next twelve months. This suggests a possible upside of 14.6% from the stock's current price. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Has Novartis been receiving favorable news coverage?

Media coverage about NVS stock has trended somewhat positive on Friday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a news impact score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the immediate future.

Are investors shorting Novartis?

Novartis saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 2,863,518 shares, an increase of 62.5% from the March 15th total of 1,761,695 shares. Based on an average daily volume of 2,516,349 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.1% of the shares of the company are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Intel (INTC), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Pfizer (PFE), Walt Disney (DIS), NVIDIA (NVDA), Cisco Systems (CSCO), AbbVie (ABBV), Merck & Co., Inc. (MRK) and Bank of America (BAC).

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.14%), Bristol John W & Co. Inc. NY (0.03%), Country Trust Bank (0.02%), Welch Group LLC (0.01%), Gofen & Glossberg LLC IL (0.01%) and Confluence Investment Management LLC (0.01%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Pennsylvania Trust Co, Country Trust Bank, Park National Corp OH, Harel Insurance Investments & Financial Services Ltd., Ingalls & Snyder LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA and Bristol John W & Co. Inc. NY.

Which institutional investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates, Mercer Global Advisors Inc. ADV, Benson Investment Management Company Inc., Shorepoint Capital Partners LLC, LaFleur & Godfrey LLC, We Are One Seven LLC, FNY Investment Advisers LLC and First Manhattan Co..

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $76.41.

How big of a company is Novartis?

Novartis has a market capitalization of $176.51 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.

What is Novartis' official website?

The official website for Novartis is http://www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NYSE NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  431 (Vote Outperform)
Underperform Votes:  499 (Vote Underperform)
Total Votes:  930
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel